Chronic arsenic exposure is associated with the development of several cardiovascular (CV) diseases, including hypertension, carotid atherosclerosis and microvascular abnormalities. Upregulation of systemic and aortic angiotensin II (ANGII) signaling has been proposed to contribute to arsenic-induced vascular dysfunction. However, the underlying mechanisms of ANGII signaling augmentation and of the attendant pathological effects on the CV system induced by arsenic remain largely unknown. Here, we reported that exposure of human umbilical vein endothelial cells (HUVECs) to arsenite resulted in elevation of angiotensinogen (AGT, the precursor of ANGII), angiotensin-converting enzyme (ACE, the enzyme critical for ANGII generation), and ANGII type I receptor (AT1R) synthesis as well as increased ANGII production. Further investigations showed that endoplasmic reticulum (ER) stress was induced and activation of the IRE1a/XBP1s arm of the unfolded protein response was responsible for the augmented ACE/ANGII/AT1R axis components in arsenite-treated HUVECs. Moreover, XBP1s promoted HIF1a accumulation, and inducible XBP1s/HIF1a complex formation was required to drive the transcription of AGT, ACE, and AT1R under arsenite exposure. Ablation of IRE1a/XBP1s/HIF1a-dependent ANGII signaling activation inhibited oxidative stress and proinflammatory response induced in HUVECs by arsenite. These results thus have revealed the novel role of ER stress-coupled HIF1a pathway activation in mediating ANGII-dependent endothelial cell dysfunction upon arsenite exposure. Therefore, searching for strategies to alleviate endothelial ER stress or ANGII signaling might be helpful for managing arsenite-induced CV disorders.
carotid atherosclerosis, and microvascular abnormalities (Balakumar and Kaur, 2009; Chen et al., 1995 Chen et al., , 1996 Hsueh et al., 1998; Rahman et al., 1999; States et al., 2009; Stea et al., 2014; Tseng et al., 2000; Wang et al., 2002; ) . Experimental studies also indicate a causal relationship between subchronic exposure to high levels of arsenite (>50 ppm) through drinking water and the incidence of vascular dysfunction and systemic hypertension in rats (Balakumar and Kaur, 2009; Kesavan et al., 2014; Khuman et al., 2016; Sarath et al., 2014; Sharma and Sharma, 2013; States et al., 2009; Stea et al., 2014; Waghe et al., 2015; Yang et al., 2007) . Compared with the well-studied mechanisms involved in arsenic-induced tumorigenesis, the understanding of the intracellular signaling events by which arsenic invokes CV dysfunction is still limited (Balakumar and Kaur, 2009; Ellinsworth, 2015; Hubaux, et al., 2013; Hunt, et al., 2014; States et al., 2009; Stea et al., 2014) .
The renin-angiotensin system (RAS), an integrated system of bioactive peptides, plays a major role in the pathophysiology of CV disorders. Angiotensin II (ANGII), the extensively characterized peptide produced by angiotensin-converting enzyme (ACE)-mediated cleavage of angiotensinogen (AGT), contributes to the advancement of CV diseases by inducing vasoconstrictive effects, endothelial dysfunction, inflammatory reactions, thrombosis, and oxidative injuries (Brasier, 2002) . At increased levels, ANGII elicits several deleterious effects on vessel walls by activating ANGII type 1 receptor (AT1R)-dependent signaling (Te Riet et al., 2015) .
Recent experimental studies in rats have revealed that arsenic exposure produces systemic hypertension with concomitant increases in plasma ANGII and ACE levels, as well as aortic AT1R protein expression (Waghe et al., 2015) . Moreover, an AT1R antagonist can ameliorate arsenic-induced systemic hypertension by reducing the activation of ANGII signaling pathways (Khuman et al., 2016) . These data have thus suggested the critical role of inappropriate RAS activation in mediating arsenite-induced hypertensive vascular disorders. However, the mechanism responsible for augmented activity of the ACE/ ANGII/AT1R axis under arsenite exposure remains underdetermined.
The endoplasmic reticulum (ER) is the site of synthesis and maturation of proteins designed for secretion or localization on the cell membrane. Various types of stress disturb ER function, causing unfolded or misfolded proteins to accumulate in the ER and thus induce ER stress. The unfolded protein response (UPR) is considered an adaptive reaction to prevent accumulation of unfolded and misfolded proteins in the ER and improve normal ER function. In the ER, 3 proteins are able to sense an increase in misfolded polypeptides and then initiate UPR (Bravo et al., 2013) . The UPR sensors include double-stranded RNA-activated protein kinase-like ER kinase (PERK), activating transcription factor 6 (ATF6), and inositol-requiring kinase 1 (IRE1a). Activation of these three UPR sensors has been found to play important roles in the onset and progression of CV disorders, such as atherosclerosis, cardiac hypertrophy, ischemic heart disease and heart failure (Bravo et al., 2013; Gotoh et al., 2011) .
To ascertain the mechanism responsible for abnormal RAS activation in the pathogenesis of arsenite-induced hypertensive vascular disorders, we used human umbilical vein endothelial cells (HUVECs) in the current study because the most sensitive target of arsenic toxicity in the vasculature is the endothelium (Ellinsworth, 2015) . Here, we demonstrated that arsenite exposure induced ACE/ANGII/AT1R axis activation and subsequent oxidative stress and proinflammatory responses in HUVECs. Most importantly, induction of the IRE1a/XBP1s arm of the UPR and the assembly of an XBP1s/hypoxia-inducible factor 1a (HIF1a) transcriptional complex are essential for driving the transcription of RAS components and the endothelial cell dysfunction resulting from arsenite exposure. These novel findings have thus elucidated a previously unidentified mechanism that controls vascular RAS activity by UPR-dependent transcriptional events and their contribution to arsenite-induced CV pathologies.
MATERIALS AND METHODS
Cells and reagents. HUVECs were purchased from the American Type Culture Collection (ATCC) and maintained in DMEM (Life Technologies) with 10% fetal bovine serum (Life Technologies) supplemented with antibiotic-antimycotic solution (Life Technologies). Antibodies against IRE1a, phospho-PERK (Thr980), PERK, HIF1a, XBP1s, and ACTB were purchased from Cell Signaling Technology (Beverly, Massachusetts). Antibodies against ATF6, AGT, ACE, and AT1R were obtained from Santa Cruz Biotechnology (Santa Cruz, California). Human PERK siRNA, IRE1a siRNA, XBP1s siRNA, HIF1a siRNA, and their control siRNAs were purchased from Ruibo Biotechnology (Guangzhou, China). Sodium arsenite, enalapril, and valsartan were purchased from Sigma (St. Louis, Missouri).
Selection of arsenic concentration. Epidemiological studies in parts of the world with high levels of arsenic (300, 700, 864, or 930 lg/l or even higher) in their groundwater have associated arsenic exposure with elevated risks for an array of CVD (Chen et al., 1995 (Chen et al., , 1996 Hsueh et al., 1998; Rahman et al., 1999; States et al., 2009; Tseng et al., 2000; Wang et al., 2002) . For the experimental studies in rats, people usually selected the concentration of sodium arsenite that was over 50-fold higher than the environmental levels of arsenic contamination (50, 100 ppm or even higher) because only arsenite exposure through drinking water at these levels can recapitulate the obvious CV effects in experimental animals (Kesavan et al., 2014; Khuman et al., 2016; Sarath et al., 2014; Sharma and Sharma, 2013; States et al., 2009; Waghe et al., 2015; Yang et al., 2007) . We believe that the main reason for this discrepancy is that the subjects in the epidemiological studies have usually suffered chronic exposure to environmental arsenic for years, which might result to arsenic deposition in vivo. In contrast, laboratory studies are reported to finish within 8-180 days. Accounting for the daily water consumption of the animals, a high level of arsenic is required to induce CV disorders subchronically. However, because no previous studies have reported the serum arsenite level of the population or experimental animals after a period of arsenic exposure through drinking water, the serum arsenite concentrations to which human and rat vascular endothelial cells are exposed in vivo remain unknown.
In in vitro studies using human or mouse endothelial cell lines, treatment of the cells with 5 lM of sodium arsenite for 24 h was reported to induce endothelial dysfunction (Hossain, et al., 2013; Ma et al., 2017; Smith et al., 2001) . Based on these reports, to characterize the dose-response relationship of arsenic-induced ANGII signaling activation in HUVECs, we tested the effect of 1.25, 2.5, 5, 10, and 20 lM of arsenite in the preliminary experiments. As 1.25 and 2.5 lM of arsenite had weak and 20 lM of arsenite had the strongest inducing effect on ANGII signaling in HUVECs, we finally selected 5, 10, and 20 lM of arsenite to analyze the dose-dependent response and 20 lM of arsenite to test the single dose response in this study.
Luciferase reporter assay. Luciferase activity was tested using a firefly-Renilla Dual-Luciferase Reporter Assay System (Promega). In brief, HUVECs were co-transfected with a hypoxia-responsive element (HRE)-driven luciferase reporter (Dong et al., 2012) and a Renilla luciferase reporter as the internal control, after which the cells were subjected to arsenite exposure. The data were obtained by normalizing the activity of the experimental reporter to that of the internal control. The results were presented as the relative induction by normalizing the luciferase activity in the arsenite-treated cells to the luciferase activity in untreated control cells, as previously described (Dong et al., 2012) . Each sample was tested in triplicate. Three independent experiments were performed.
RT-PCR assay.
To analyze the induction of AGT, ACE, and AT1R transcription in HUVECs under arsenite exposure, total RNA was extracted with TRIzol Reagent (Sigma-Aldrich) and cDNA was synthesized with the ThermoScript RT-PCR system (Thermo Fisher Scientific). The following oligonucleotides were synthesized and used as the specific primers to amplify human AGT, ACE, or AT1R cDNAs: human AGT: forward: 5 0 -tcccctgtggat- titative evaluation of the mRNA levels of RAS components, the bands were scanned and the intensity was quantified by densitometric analysis using Gel-Pro Analyzer software. The data were normalized to an internal control (ACTB) and expressed as relative density of mRNA. Three independent experiments were performed, and the final quantitative results were presented as the mean6 SD.
ChIP assay. A ChIP assay was performed using an Enzymatic Chromatin IP Kit (Cell Signal Biotechnology) according to the protocol recommended by the manufacturer. ChIP primers were designed to specifically amplify the regions covering the putative HIF1a-and XBP1s-responsive elements within the human AGT, ACE, and AT1R promoters. The sequences of the primers were as follows: AGT: forward: 5 0 -attgttcagtcagtgaatgtacag-3 0 , re-
Three independent experiments were performed.
Western blot assay. After treatment, HUVECs were harvested and lysed with ice-cold cell lysis buffer (10 mM Tris-HCl, pH 7.4, 1% SDS and 1 mM Na 3 VO 4 ), and the homogenate was centrifuged to collect the supernatant. The harvested samples were quantified using a protein assay kit, separated by SDS-PAGE, and transferred to a PVDF membrane. After being blocked with skim milk, the blots were probed with the appropriate primary antibodies overnight at 4 C before being washed and incubated with the appropriate horseradish peroxidase (HRP)-conjugated secondary antibodies (Cell Signaling Technology). Bands were detected as described in our previous report (Dong et al., 2012) . Three independent experiments were performed.
Immunoprecipitation. To detect the interaction between endogenous XBP1s and HIF1a in HUVECs under arsenite exposure, cell lysates were prepared with ice-cold cell lysis buffer (10 mM TrisHCl, pH 7.4, 1% SDS and 1 mM Na 3 VO 4 ) and then subjected to immunoprecipitation with an anti-XBP1s antibody. The immunoprecipitants were subjected to a Western blot assay with an anti-HIF1a antibody. Three independent experiments were performed.
Immunofluorescence assay. To determine the levels of AT1R, vascular cell adhesion molecule 1 (VCAM-1), endothelial selectin (E-selectin) and platelet selectin (P-selectin) on the surfaces of HUVECs, cells were incubated with FITC-conjugated antibodies (eBioscience). The stained cells were analyzed on a FACSCalibur using CellQuest software (Becton Dickinson). Three independent experiments were performed.
ELISAs. The production of cytokines and peptides [ANGII, soluble intercellular adhesion molecule-1 (sICAM-1), interleukin 8 (IL-8) and monocyte chemoattractant protein-1 (MCP-1)] in the cell culture supernatants of HUVECs was quantified with immunoassay kits (Jitai Biotechnology and Guduo Biotechnology) according to the manufacturers' protocols. The standard cytokines or peptides provided by the kit were serially diluted and then tested with the cell culture supernatants of HUVECs under the same conditions. An OD-concentration curve was drawn according to the absorbance values of the standards. Then, the samples were quantified according to the OD-concentration curve of the standards. Each sample was tested in triplicate.
Three independent experiments were performed. Statistics. The data were tested for significance by using Student's t-test to determine the effect of treatment within a group or factorial design (AVONA) to determine the effects of treatment Âgroup interactions . The results were presented as the mean 6 SD. The level of significance was set at p < .05.
RESULTS

Arsenite Exposure Elevated the Expression of ACE/ANGII/AT1R Axis Components in HUVECs
Although the previous data from animal models demonstrated the elevation of serum ANGII and ACE as well as aortic AT1R expression in response to arsenite exposure (Khuman et al., 2016; Waghe et al., 2015) , they did not provide any in vivo evidence for the exact source of these increased RAS components. Since the most sensitive target of arsenic toxicity in the vasculature is the endothelium (Ellinsworth, 2015) , we thus assumed that the increase in the syntheses of ACE/ANGII/AT1R axis components in the vascular endothelial cells might contribute to the augmented levels of circulating and aortic RAS peptides under arsenite exposure. From this point of view, we performed in vitro assays by using HUVECs in this study.
First, HUVECs were treated with different doses of arsenite, and the expression levels of AGT, ACE, and AT1R were determined 12 h later. As shown in Figures 1A, B and E, AGT, ACE, and AT1R transcription as well as their protein synthesis were significantly upregulated following arsenite treatment at different doses, and the peak induction of these components was Figure 1 . Arsenite exposure induced expression of ACE/ANGII/AT1R axis components in HUVECs. A, HUVECs were treated with different doses of arsenite, and then the transcription levels of AGT, ACE, and AT1R were determined by RT-PCR at 12 h after arsenite exposure. B, Quantitative evaluation of AGT, ACE, and AT1R mRNA in (A) was performed by densitometric analysis. C, HUVECs were treated with a single dose of arsenite (20 lM) for the time periods indicated, and then the transcription levels of AGT, ACE, and AT1R were determined. D, Quantitative evaluation of AGT, ACE, and AT1R mRNA in (C) was performed by densitometric analysis. E, HUVECs were treated as described in (A), and the protein synthesis of AGT, ACE, and AT1R was determined by Western blots at 12 h after arsenite exposure. F, HUVECs were treated as described in (C), and the protein synthesis of AGT, ACE, and AT1R was determined by Western blots at the indicated time periods after arsenite exposure.
G-H, HUVECs were treated with arsenite (20 lM) for 24 h, and then ANGII production in the cell supernatants and cell surface levels of AT1R were determined by ELISAs and flow cytometric assays, respectively (**, p < .01).
observed upon 20 lM of arsenite exposure. Then, HUVECs were exposed to this single dose of arsenite, and the levels of RAS components were determined after different time periods. As shown in Figures 1C, D and F, a dramatic increase in the transcription and protein synthesis of AGT, ACE, and AT1R was detected at 6 h after arsenite exposure and was sustained for 24 h. Furthermore, ELISAs and flow cytometric assays showed elevated production of ANGII in the supernatants of HUVECs ( Figure 1G) and enhancement of the cell surface level of AT1R within 24 h after arsenite treatment ( Figure 1H ). These results indicate that arsenite exposure is capable of inducing augmentation of ACE/ANGII/AT1R axis components in the vascular endothelial cells, which causes a parallel increase in the formation of secretory ANGII.
The IRE1a/XBP1s Branch of the UPR Contributed to the Augmentation of ACE/ANGII/AT1R Axis Components in HUVECs Upon Arsenite Exposure ER stress and UPR have been demonstrated to play important roles in the onset and progression of CV pathologies (Chistiakov et al., 2014; Gotoh et al., 2011) . Therefore, we next detected whether UPR is involved in the augmentation of RAS components in arsenite-treated HUVECs. As shown in Figure 2A , arsenite treatment induced a significant increase in the expression of IRE1a and the spliced form of XBP1 (XBP1s) and in PERK phosphorylation in HUVECs, while the levels of ATF6 before and after arsenite exposure did not appear to be different, indicating that two arms of the UPR could be activated by arsenite. In the next experiment, siRNAs targeting the PERK and IRE1a/XBP1s branches of the UPR were separately transfected into HUVECs. In that experiment, we observed similar levels of AGT, ACE, and AT1R induction in the absence or presence of PERK activation upon arsenite exposure ( Figure 2B ), while the augmentation of these RAS components was almost totally blocked when IRE1a/ XBP1s pathway activation was interrupted (Figs. 2C and 2D) . Consistently, induction of AGT, ACE, and AT1R transcription was also dramatically suppressed in response to the same arsenite exposure conditions (Figs. 2E-H) . Furthermore, the increase in ANGII generation induced by arsenite was also impaired in both IRE1a and XBP1s siRNA-transfected HUVECs ( Figure 2I ). These data together indicate that the IRE1a/XBP1s arm of the UPR is involved in the elevation of transcription and protein synthesis of ACE/ANGII/AT1R axis components induced in vascular endothelial cells by arsenite.
HIF1a Functioned as a Partner for XBP1s in Mediating the Induction of RAS Components in HUVECs Under Arsenite Exposure
Next, we tried to ascertain the detailed mechanism by which IRE1a/XBP1s pathway activation mediated the inducible transcription of ACE/ANGII/AT1R axis components in arsenitetreated HUVECs. After analyzing the À1000 bp regions of the human AGT, ACE, and AT1R gene promoters, we identified potential cis-acting DNA regulatory elements that perfectly matched the binding sequence for XBP1s (TC/GATGTC/TT) (http://jaspar. genereg.net/) ( Figure 3A) . Interestingly, the binding sites for HIF1a were also identified close to or overlapping with XBP1s-responsive elements within the promoter regions of these three genes ( Figure 3A) . Therefore, we supposed that XBP1s and HIF1a might have a synergistic effect in driving the transcription of ACE/ANGII/AT1R axis components in response to arsenite exposure. To address this possibility, we first determined whether HIF1a was involved in the transcriptional induction of AGT, ACE and AT1R in arsenite-treated HUVECs. As shown in Figure 3B , arsenite treatment induced a dose-dependent accumulation of HIF1a in HUVECs and the peak induction of HIF1a was observed at 20 lM of arsenite exposure. When HRE-driven luciferase reporter-transfected HUVECs were exposed to this single dose of arsenite for different time periods, a sustained elevation of HRE-driven luciferase activity could be readily observed within 24 h ( Figure 3C ), indicating that HIF1a could be activated in HUVECs upon arsenite treatment. Moreover, when HIF1a induction was suppressed, both the transcription and the protein synthesis of AGT, ACE, and AT1R were totally blocked in arsenite-treated HUVECs (Figs. 3D-F) . Under the same experimental conditions, induced production of ANGII was also significantly inhibited ( Figure 3G ). Taking this evidence together, we conclude that HIF1a is involved in the transcriptional induction of ACE/ANGII/AT1R axis components in arsenite-treated HUVECs.
Next, we focused on elucidating the functional link between XBP1s and HIF1a in arsenite-induced responses. As shown in Figures 4A and 4B , knockdown of either IRE1a or XBP1s expression completely blocked HIF1a accumulation in HUVECs under arsenite exposure, indicating that IRE1a/XBP1s pathway activation is required for HIF1a induction in arsenite-treated vascular endothelial cells. In the next experiment, the immunoprecipitation assay revealed the formation of an inducible XBP1s/HIF1a complex upon arsenite exposure ( Figure 4C ). In addition, both XBP1s and HIF1a displayed similarly strong activity in associating with the same chromatin regions of the AGT, ACE, and AT1R promoters according the results of the ChIP assay ( Figure 4D ). Most importantly, when HIF1a induction was impaired, XBP1s lost its ability to recruit to the promoter regions within RAS component genes ( Figure 4E ). These results together indicate that HIF1a functions as a downstream target, partner, and critical determinant of XBP1s to trigger the transcription of ACE/ ANGII/AT1R axis components in response to arsenite exposure.
ANGII/AT1R Cascade Activation Was Implicated in ArseniteInduced Oxidative Stress and Proinflammatory Responses in HUVECs
After revealing ER stress-coupled HIF1a pathway activation that mediates the induction of RAS components in arsenite-treated HUVECs, we next tried to examine whether augmented ANGII signaling could exert any downstream pathological effect through its receptor, AT1R. Since inappropriate ANGII/AT1R pathway activation plays a critical role in the initiation and maintenance of endothelial dysfunction mainly by triggering proinflammatory and oxidative stress responses (Brasier, 2002) , we therefore detected the expression levels of chemokines and cell adhesion molecules driving vascular inflammation and the regulators of oxidative stress responses in HUVECs under arsenite exposure. The results of ELISAs and flow cytometric assays demonstrated that HUVECs produced more E-selectin, sICAM-1, IL-8, and MCP-1 after arsenite treatment (Figs. 5A-D) . Under the same conditions, a significant increase in adhesion of U937 monocytes to HUVECs was readily observed in the co-culture assay (Figs. 5E and 5F ). These data indicate that arsenite is potent in upregulating the expression of chemokines and cell adhesion molecules in the vascular endothelial cells, which contributes to recruiting monocytes and thus induces a proinflammatory response. In the subsequent experiment, we also found the elevation of ROS and MDA production in arsenitetreated HUVECs (Figs. 5G and 5H ), indicating that arsenite exposure is also capable of inducing an oxidant/antioxidant imbalance in vascular endothelial cells.
Next, arsenite-induced ANGII signaling activation was prevented by pretreatment of HUVECs with either an ACE inhibitor, AT1R were determined at 12 h after arsenite exposure. E and G, HUVECs were transfected and treated with arsenite as described in C and D, and then AGT, ACE, and AT1R mRNA transcription levels were determined at 12 h after arsenite exposure. F and H, Quantitative evaluation of AGT, ACE, and AT1R mRNA in E and G was performed by densitometric analysis. I, HUVECs were transfected with IRE1a or XBP1s siRNA or their control siRNAs and then subjected to arsenite (20 lM) exposure at 36 h after transfection. ANGII production in cell supernatants was determined by ELISA at 24 h after arsenite exposure (**, p < .01).
enalapril, or an AT1R antagonist, valsartan, and then the changes in the mediators of vascular injury were determined. We found that interrupting ANGII/AT1R cascade activation resulted in downregulation of E-selectin, sICAM-1, IL-8, and MCP-1 synthesis to different extents (Figs. 6A-D) . Furthermore, arsenite-induced adhesion of U937 monocytes to HUVECs was almost totally blocked with the impairment of ANGII signaling activation (Figs. 6E and 6F) . Meanwhile, ROS and MDA generation were also significantly suppressed when ANGII/AT1R axis activation was blocked upon arsenite treatment (Figs. 6G and 6H) . These data together indicate that augmented ANGII signaling is implicated in oxidative stress and proinflammatory responses and thus contributes to endothelial cell dysfunction under arsenite exposure. A, An analysis of human AGT, ACE, and AT1R promoters indicated the potential XBP1s-and HIF1a-responsive elements located closely or overlapping within the promoter regions of these 3 genes. B, HUVECs were treated with different doses of arsenite, and then the accumulation of HIF1a was determined at 12 h after arsenite exposure. C, HUVECs were transfected with an HRE-driven luciferase reporter and then exposed to arsenite (20 lM) at 36 h after transfection. The induction of HRE-dependent luciferase activity was determined at the indicated time periods after arsenite exposure (**, p < .01). D, HUVECs were transfected with HIF1a siRNA or its control siRNAs and then treated with arsenite (20 lM) at 36 h after transfection. The transcription levels of AGT, ACE, and AT1R were determined at 12 h after arsenite exposure. E, Quantitative evaluation of AGT, ACE, and AT1R mRNA in (D) was performed by densitometric analysis. F, HUVECs were transfected and treated with arsenite as described in (D), and the protein synthesis of AGT, ACE, and AT1R was measured at 12 h after arsenite exposure. G, HUVECs were transfected and treated with arsenite as described in (D). ANGII production in cell supernatants was determined by ELISA at 24 h after arsenite exposure (**, p < .01).
IRE1a/XBP1s/HIF1a Pathway Activation Mediated ANGII-Dependent Endothelial Cell Dysfunction Under Arsenite Exposure To determine whether IRE1a/XBP1s/HIF1a signaling pathway activation, which mediates augmented ACE/ANGII/AT1R axis components, also contributes to regulating endothelial cell dysfunction in response to arsenite, IRE1a, XBP1s and HIF1a siRNAs were separately transfected into HUVECs to block the activation the of IRE1a/XBP1s/HIF1a pathway at different levels. We observed significant inhibition of arsenite-induced E-selectin, sICAM-1, IL-8, and MCP-1 synthesis (Figs. 7A-D) as well as the adhesion of U937 cells to HUVECs under these siRNA-transfected conditions (Figs. 7E and 7F) . Meanwhile, production of ROS and MDA was also dramatically suppressed (Figs. 7G and 7H) . Taken together, these data indicate that IRE1a/XBP1s/HIF1a pathway activation is critical for mediating ANGII-dependent endothelial cell dysfunction in response to arsenite exposure.
DISCUSSION
The epidemiological association between chronic arsenic exposure and CV dysfunction is well known, but the underlying mechanisms driving the pathological effect of arsenic on the CV system remain far from being clarified. According to the results of two recent reports, arsenic exposure causes enhancement of systemic ANGII signaling, thus leading to the impairment of vascular physiology and contributing to the development of hypertension in rats (Khuman et al., 2016; Waghe et al., 2015) . Since abnormal ANGII signaling activity has been shown to play roles in a wide range of CV pathologies, such as hypertension, myocardial infarction, stroke, congestive heart failure, and atherosclerosis (Brasier, 2002; Te Riet et al., 2015) , elucidating the molecular basis for the alteration in ANGII signaling and the attendant pathological effects on the vasculature might provide a common mechanism involved in arsenic-induced CV disorders. termined at 12 h after arsenite exposure. C, HUVECs were left untreated or treated with arsenite (20 lM) for 12 h. Cell lysate was immunoprecipitated with an antiXBP1s antibody, and the immunoprecipitants were analyzed by a Western blot assay with an anti-HIF1a antibody to detect the binding ability of XBP1s to HIF1a. D, Soluble chromatin was prepared from HUVECs that had been either untreated or treated with arsenite (20 lM) for 12 h, and then immunoprecipitated with anti-XBP1s, anti-HIF1a, or control IgG antibodies. The DNA extracts were amplified with primers that covered the putative XBP1s or HIF1a binding sites within the human AGT, ACE, and AT1R promoters. E, HUVECs were transfected and treated as described in Figure 3D . Soluble chromatin was prepared and then immunoprecipitated with antiXBP1s or control IgG. The DNA extracts were amplified with primers that covered the putative XBP1s binding sites within the human AGT, ACE, and AT1R promoters. MCP-1 was measured at 24 h after arsenite exposure (**, p < .01; *, p < .05). E and F, HUVECs were treated as described in A-D, and then the adhesion of U937 cells to HUVECs was measured as described in Figures 5E and F (**, p < .01). G and H, HUVECs were treated as described in A-D, and then generation of ROS and MDA was determined at 24 h after arsenite exposure (**, p < .01; *, p < .05). Figure 7 . IRE1a/XBP1s/HIF1a pathway activation mediated ANGII-dependent endothelial cell dysfunction in arsenite-treated HUVECs. A-D, HUVECs were transfected with IRE1a, XBP1s, or HIF1a siRNA or their control siRNAs and then were subjected to arsenite (20 lM) exposure at 36 h after transfection. The production of E-selectin, sICAM-1, IL-8, and MCP-1 was measured at 24 h after arsenite exposure (**, p < .01). E and F, HUVECs were transfected and treated with arsenite as described in A-D, and then the adhesion of U937 cells to HUVECs was evaluated as described in Figures 5E and 5F (**, p < .01). G and H, HUVECs were transfected and treated as described in A-D, and then the generation of ROS and MDA was measured at 24 h after arsenite exposure (**, p < .01).
Furthermore, it is well accepted that the most sensitive target of arsenic toxicity in the vasculature is the endothelium (Ellinsworth, 2015) ; therefore, in this study, we selected the human vascular endothelial cell line as a model to determine whether arsenite exposure could activate ANGII signaling and the mechanisms involved. The data from this study provide the first in vitro evidence for the elevated synthesis of RAS components as well as the oxidative stress and proinflammatory responses ensued in human vascular endothelial cells under arsenite exposure. Considering our results together with a previous report from another group about the upregulation of ANGII receptor production in an arsenite-treated mouse aortic endothelial cell line (Hossain et al., 2013) , we believe that endothelial ACE/ANGII/AT1R axis activation might make a large contribution to the systemic upregulation of ANGII and the attendant vascular pathologies in response to arsenic exposure. Therefore, maintaining vascular endothelial homeostasis by controlling ANGII signaling might be beneficial for the management of the CV burden induced by arsenic.
To control the inappropriate ANGII signaling activation in the vascular endothelium, we must identify the responsible upstream signal transduction pathway(s) that mediate the augmentation of endothelium-derived ACE/ANGII/AT1R axis components induced by arsenite. It is generally accepted that AGT abundance is predominantly regulated at the transcriptional level (Brasier, 2002) . Furthermore, many of the transcription factors that are involved in the regulation of AGT transcription have been identified, including signal transducer and activator of transcription 1/3/5B (STAT1/ 3/5B), nuclear factor-jB (NF-jB), upstream stimulatory factors 1/2 (USF1/2), hepatocyte nuclear factor 1a/4 (HNF1a/4), forkhead box class O1 (Foxo1), and activator protein-1 (AP-1) (Han et al., 2009; Lai et al., 2013; Park et al., 2012; Qi et al., 2014; Satou and GonzalezVillalobos, 2012) . However, most results regarding AGT transcription have been obtained in hepatic cells, pulmonary epithelial cells, fibroblast cells or adipose tissues, whereas no previous reports have elucidated the transcriptional control of AGT in vascular endothelial cells (Han et al., 2009; Lai et al., 2013; Park et al., 2012; Qi et al., 2014; Satou and Gonzalez-Villalobos, 2012) . Therefore, to our knowledge, this study is the first to identify the XBP1s-binding site within the promoter region of AGT and subsequently disclose the critical role of XBP1s-dependent ER stress in mediating AGT transcription in vascular endothelial cells. It is noteworthy that all of the previous reports regarding the effects of ER stress induced by arsenic exclusively show pro-apoptotic effects in a variety of malignant and nonmalignant cells (Binet et al., 2010; Chiu et al., 2015; Foufelle and Fromenty, 2016; Gu et al., 2016; Lu et al., 2011; Wang et al., 2016) . Therefore, the results of this study not only expand on the former mechanism by characterizing the novel role of arsenic-induced ER stress in mediating vascular pathologies unrelated to apoptosis, but also elucidate a previously unidentified mechanism that controls vascular RAS activity by UPR-dependent transcriptional signals. Therefore, governing IRE1a/XBP1s pathway activation may be a useful way to limit deleterious ANGII-dependent effects in the vascular system under arsenic exposure.
One of the most fascinating yet vastly understudied areas in ER stress biology involves the context-specific, dimerizationmediated activity of UPR transcription factors, which greatly expand the scope of potential target genes controlled by UPR (Bettigole and Glimcher, 2015) . XBP1s has been reported to directly interact with HIF1a in triple-negative breast cancer cells in a previous study, and this interaction is critical for maximal induction of HIF1a target genes. However, it has been reported that XBP1s does not affect HIF1a accumulation and merely forms a heterodimer with HIF1a to cooperatively recruit RNA polymerase II to target promoters and then drive transcription . In contrast to this previous finding, we have revealed the novel action of XBP1s in regulating HIF1a protein stability in response to arsenite. Moreover, interacting with HIF1a was demonstrated to be the prerequisite step for XBP1s to occupy the corresponding responsive elements within the promoter regions of the target genes in the RAS system. Thus, these data have revealed the novel action of HIF1a in determining the transcriptional activity of XBP1s in response to arsenite exposure.
We notice that XBP1 activation has been demonstrated to contribute greatly to maintaining the physiological integrity of endothelial cells and to promote endothelial proliferation and angiogenesis in the ischemic tissue, yet it triggers a proapoptotic signal in the endothelial cells via inducing autophagy or suppressing VE-cadherin expression, thus leading to atherosclerosis development under other stress conditions Zeng et al., 2009 Zeng et al., , 2013 . That means XBP1 splicing is able to play diverse roles in regulating endothelial function. Due to the newly discovered XBP1s-dependent transcriptional events related to ACE/ANGII/AT1R axis augmentation in arsenite-treated HUVECs, the data in our current study have also expanded our understanding of the action of XBP1 splicing in mediating endothelial pathologies.
In summary, we have provided novel evidence for the contribution of ER instability and the IRE1a/XBP1s branch of UPRlinked HIF1a transactivation in mediating ANGII-dependent endothelial cell dysfunction. Thus, searching for strategies to alleviate ER stress and restore vascular RAS homeostasis might be helpful for preventing CV disorders induced by arsenic.
FUNDING
